Benzocaine 20% / Lidocaine 10% / Tetracaine 10%

Research Summary

Mechanism & Physiological Role

Three surface anesthetics in one vehicle, spanning both structural classes. Benzocaine and tetracaine carry an ester linkage while lidocaine carries an amide, and the two classes are cleared by different routes.

Clinical & Research Applications

Discussed in the procedural dermatology and anesthesia literature on topical anesthesia, on systemic absorption from high-concentration preparations, and on benzocaine-associated methemoglobinemia.

Biosynthesis, Handling & Sourcing

Every local anesthetic is assembled the same way, from an aromatic ring, a linking group and an amine tail, and the linker is what sorts them into classes. This preparation contains both. Benzocaine and tetracaine are ester-linked; lidocaine is amide-linked. That single bond decides the clearance route, because esters are hydrolysed in plasma by cholinesterases while amides are metabolised hepatically. It also decides what the breakdown yields: ester hydrolysis releases para-aminobenzoic acid, which is the origin of the older reputation esters carry for sensitisation.

Two further properties do most of the remaining work. The pKa of each molecule fixes what proportion exists as the neutral base at tissue pH, and it is the neutral form that crosses membranes, so pKa is what governs onset. Lipid solubility tracks potency. Benzocaine is the outlier of the three: it has no ionisable amine tail, so it stays uncharged across the physiological range and partitions unlike the other two. Combining actives with different pKa values and different partition behaviour is the reason a prescriber specifies a combination rather than a single agent.

For procurement the governing question is what happens when a high-concentration cream meets a large surface area or an occlusive dressing. Systemic exposure rises with concentration, with the area covered and with occlusion time. The published pharmacokinetic work on lidocaine and tetracaine topicals sits at lower concentrations than compounded creams generally use, so those measurements describe their own conditions and do not extrapolate upward on their own. The anaesthesia literature has moved in the same direction from the other side: recent reviews describe lidocaine as the agent now driving systemic toxicity reports, and question how well the evidence base supports mixing local anesthetics at all, which is precisely what a three-active cream does. Benzocaine carries a separate and well documented association with methemoglobinemia at topical concentrations, described in case series as uncommon rather than rare. FDA has published a consumer warning aimed specifically at topical products carrying anesthetic actives above approved-product concentrations.

As a compounded preparation this is made to a prescriber-specified combination for a named patient rather than manufactured to a fixed formula, which is what allows a three-active ratio to exist at all. It is supplied in a pump rather than a jar, which keeps an in-use date defensible by avoiding repeated open-container exposure. It is non-sterile and compounded under USP General Chapter 795, and the beyond-use date printed on the container is assigned at preparation and governs. This composition is not FDA-approved, and compounded medications are not FDA-approved finished drug products. Nothing here is direction on quantity, area or duration of application, all of which are prescriber decisions.